Navigating CMC Complexity: Overcoming Manufacturing & Cost Barriers to Advance Next-Generation Oligonucleotide Therapeutics

• Why multi-component designs present unique manufacturing and regulatory hurdles to understand the CMC burden of novel oligos
• New approaches to reduce cost and complexity: Including, enzymatic ligation, and emerging scalable manufacturing technologies
• Building global manufacturing readiness: Evaluating current capacity and capabilities to meet growing demand for large-scale, GMP-compliant oligonucleotide production

Speakers:

Hagen Cramer

Chief Technology Officer

QurAlis